Pfizer and Allergan are in the final stages of merger discussions, according to CNBC sources, with an announcement expected the Monday after Thanksgiving.
The price being discussed is $370 to $380 per share, valuing Allergan at as high as $150 billion.
A $380 per share deal would beat out Pfizer’s $116 billion purchase of Warner-Lambert in 2000 as the biggest transaction in history between drug companies, according to Bloomberg-compiled data.
Additionally, buying Dublin-based Allergan would allow New York-based Pfizer to relocate outside the U.S. for tax purposes, a common strategy known as an inversion.
Read the CNBC report